Government Secrecy: Classic and Contemporary Readings
The importance and the hazards of government secrecy are now widely understood. But the principles and practices of secrecy policy as it has developed over the years remain obscure to many. A new anthology published this week aims to present “the best that has been thought and written” on the subject.
“Government Secrecy: Classic and Contemporary Readings” presents an impressive cross-section of views, from many competing and complementary perspectives. They include the theoretical (Georg Simmel), the sociological (Max Weber, Edward Shils), the adversarial (Howard Morland), and a lot more (from William Colby, Morton Halperin, Harold Relyea, Howard Zinn, James X. Dempsey, Thomas Blanton, William Weaver, Joseph Stiglitz, Lee Strickland, Herbert Foerstel, myself and others).
It is the distillation of an entire library’s worth of material that should be of interest to students of government and political science, as well as concerned citizens who find themselves confronting official secrecy.
“Government Secrecy” was edited Dr. Susan L. Maret of San Jose State University and Dr. Jan Goldman of the National Defense Intelligence College.
This strategy provides specific, actionable policy ideas to tackle the growing threat of extreme heat in the United States and was co-signed by more than 50 labor, industry, health, housing, environmental, academic and community associations and organizations.
Extreme heat has become a national economic crisis: lowering productivity, shrinking business revenue, destroying crops, and pushing power grids to the brink. The impacts of extreme heat cost our Nation an estimated $162 billion in 2024 – equivalent to nearly 1% of the U.S. GDP.
Given the rapid pace of AI advancement, a proactive effort triumphs over a reactive one. To protect consumers, workers, and the economy more broadly, it is imperative that the FTC and DOJ adapt their enforcement strategies to meet the complexities of the AI era.
To encourage greater adoption of generic drugs in clinical practice the FDA should implement a dedicated regulatory pathway for non-manufacturers to seek approval of new indications for repurposed generic drugs.